Joao Goncalves (J Goncalves, João Gonçalves)

ResearcherID ResearcherID Scopus Author ID Scopus Author ID Scopus Author ID Ciência ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2022
Publications (10 Years): 11

Top Topics

Patients With Inflammatory Bowel Disease

Rheumatoid Arthritis

Endoplasmic Reticulum

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Alimentary pharmacology & therapeutics

Advances in biochemical engineering/biotechnology

The EMBO journal

This page only lists publications with an associated author ORCID identifier.

Publications

Zvonimir Petric, Joao Goncalves, Paulo Paixao
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. Pharmaceutics 14 (9) (2022)
Rodrigo Borrega, Carlos Araújo, Nádia Aguiam, Fernando Magro, João Eurico Fonseca, Silvio Danese, João A Lopes, Joao Goncalves
Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (1) (2021)
Rodrigo Borrega, Joao Paulo Cruz, Peter Taylor, Joao Goncalves
Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (6) (2020)
Joana Ministro, Ana Margarida Manuel, Joao Goncalves
Therapeutic Antibody Engineering and Selection Strategies. Advances in biochemical engineering/biotechnology 171 (2020)
Joana H Ministro, Soraia S Oliveira, Joana G Oliveira, Miguel Cardoso, Frederico Aires-da-Silva, Sofia Corte-Real, Joao Goncalves
Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening. Applied microbiology and biotechnology 104 (6) (2020)
Rodrigo Borrega, Joao Paulo Cruz, Peter Taylor, Joao Goncalves
Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (6) (2020)
Jonathan N W N Barker, Giampiero Girolomoni, Alexander Egeberg, Joao Goncalves, Burkhard Pieper, Taegyun Kang
Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. The Journal of dermatological treatment 31 (8) (2019)
Joao Goncalves, Gihyun Myung, MinJeong Park, Deokyoon Jeong, Jeehoon Ghil
SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therapeutic advances in gastroenterology 12 (2019)
Joao Goncalves, Fernando Magro, Silvio Danese, Peter Laszlo Lakatos, Shomron Ben-Horin
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply. Alimentary pharmacology & therapeutics 48 (5) (2019)
Joao Goncalves, M Santos, R Acurcio, I Iria, L Gouveia, P Matos Brito, A Catarina Cunha-Santos, A Barbas, J Galvão, I Barbosa, F Aires da Silva, A Alcobia, M Cavaco, M Cardoso, J Delgado Alves, J J Carey, T Dörner, J Eurico Fonseca, C Palmela, J Torres, C Lima Vieira, D Trabuco, G Fiorino, Anne S Strik, M Yavzori, I Rosa, L Correia, Fernando Magro, G D'Haens, S Ben-Horin, Peter Laszlo Lakatos, S Danese
Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Alimentary pharmacology & therapeutics 48 (5) (2018)
Andreia J Amaral, Jorge Andrade, Russell B Foxall, Paula Matoso, Ana M Matos, Rui Silva Soares, Cheila Rocha, Christian G Ramos, Rita Tendeiro, Ana Serra-Caetano, José Afonso Guerra-Assunção, Mariana Santa-Marta, Joao Goncalves, Margarida Gama-Carvalho, Ana E Sousa
miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication. The EMBO journal 36 (3) (2016)